Drug Utilization and Evaluation Of Paclitaxel In Patients With Ovarian,Cervical And Breast Cancer
Main Article Content
Abstract
INTRODUCTION: Cancer is growing into a leading health and economic crisis worldwide causing over 10 million deaths in 2020.
AIMS AND OBJECTIVES:
Assessment of treatment effectiveness of paclitaxel.(Primary objective)
Assessing the drug utilization of paclitaxel in ovary, breast and cervical cancer.
To determine the correlation between menarche and menopause with occurrence of cancer in women.
To review and analyze these verity of drug associated ADRs
METHODS: Various methods were used to find out the objective of the study.
RESULTS: Out of 68 patients, 41 patients were having breast cancer, 22 patients with ovary cancer and 5 patients with cervical cancer.
CONCLUSION: Our study found that majority of the study population that is about 60% were affected by breast cancer, followed by 32% of population with the diagnosis of ovarian cancer and 7% with cervical cancer. The correlation of age at menarche and incidence of cancer in women showed the greater incidence of ovarian and breast cancer in women with early menarche. The ADR was analysed using naranjo’s scale and CTCAE grading scale and most of them experienced drug induced burning or tingling sensation, peripheral neuropathy, myalgia and hypersensitivity reaction during the chemotherapy administration.
References
Robert L. Coleman, William E. Brady, D. Scott Mc Meekin, Peter G. Rose, John T. Soper, Samuel S. Lentz, James S. Hoffman, Mark S. Shahin, A phase II evaluation of nanoparticle, albumin-bound (nab) paclitaxel in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer: A Gynecologic Oncology Group Study, Gynecologic Oncology,Volume 122, Issue 1,2011,Pages 111-115,ISSN 0090-8258
John P. Micha, Bram H. Goldstein, Connie L. Birk, Mark A. Rettenmaier, John V. Brown, Abraxane in the treatment of ovarian cancer: The absence of hypersensitivity reactions, Gynecologic Oncology, Volume 100, Issue 2, 2006,Pages 437-438,ISSN 0090-8258.
Michael Untch, Christian Jackisch, Andreas Schneeweiss, Bettina Conrad et.al, Nab-paclitaxel versus solvent-based paclitaxel inneoadjuvant chemotherapy for early breastcancer (GeparSepto—GBG 69): a randomised, phase 3 trial,The Lancet Oncology,Volume 17, Issue 3,2016,Pages 345-356,ISSN 1470-2045
Amaya, C., Luo, S., Baigorri, J.et al.Exposure to low intensity ultrasound removes paclitaxel cytotoxicity in breast and ovarian cancer cells. BMC Cancer21,981 (2021)
Mielke, Stephan, Al Sparreboom, Alex, A1 Behringer, Dirk, Al Mross, Klaus, Paclitaxel Pharmacokinetics and response to chemotherapy in patients with advanced cancer treated with weekly regimen, FD International Institute of Anticancer Research, SP 4423, OP4427, VO 25, IS 6C, YR 2005.
Akerley W, Sikov WM, Cummings F, Safran H, Strenger R, Marchant D. Weekly high-dose paclitaxel in metastatic and locally advanced breast cancer: a preliminary report Semin Oncol.1997Oct;24(5 Suppl 17):S17-87-S17-90.
Johnson DH, Paul D, Hande KR. Paclitaxel, 5-fluorouracil, and folinic acid in metastatic breast cancer: BRE-26, a phase II trial.Semin Oncol.1997 Feb;24(1 Suppl 3):S22-5.
Panagos GE. Treatment of advanced and relapsing breast cancer with a combination of paclitaxel and mitoxantrone. South-Central Hellenic Oncology Group.Semin Oncol.1997 Feb;24(1 Suppl 3):S17-21.
Gill PS, Tulpule A, Espina BM, Cabriales S, Bresnahan J, Ilaw M, Louie S, Gustafson NF, Brown MA, OrcuttC, Winograd B, Scadden DT. Paclitaxel is safe and effective in the treatment of advanced AIDS-related Kaposi's sarcoma.J Clin Oncol.1999 Jun;17(6):1876-83.
License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.